COLD + SINUS DAYTIME TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
19-10-2020
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
Tilgængelig fra:
VITA HEALTH PRODUCTS INC
ATC-kode:
M01AE51
INN (International Name):
IBUPROFEN, COMBINATIONS
Dosering:
200MG; 30MG
Lægemiddelform:
TABLET
Sammensætning:
IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG
Indgivelsesvej:
ORAL
Enheder i pakken:
10/20/24/40/50/72/96/100
Recept type:
OTC
Terapeutisk område:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Produkt oversigt:
Active ingredient group (AIG) number: 0222394001; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2011-02-08
Produktets egenskaber
PRODUCT MONOGRAPH
COLD + SINUS DAYTIME
Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
Caplets
Analgesic/Antipyretic/Nasal Decongestant
COLD + SINUS NIGHTTIME
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
and Chlorpheniramine Maleate 2 mg
Tablets
Analgesic/Antipyretic/Nasal Decongestant/Antihistamine
Vita Health Products Inc.
Date of Revision:
150 Beghin Avenue
October 19, 2020
Winnipeg, Manitoba Canada, R2J 3W2
Control # 239435
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
5
ADVERSE REACTIONS
.......................................................................................................................
13
DRUG INTERACTIONS
........................................................................................................................
23
DOSAGE AND ADMINISTRATION
....................................................................................................
27
OVERDOSAGE
......................................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................
31
STORAGE AND STABILITY
...............................................................................................................
36
SPECIAL HANDLING INSTRUCTIONS
....................................
Læs hele dokumentet
